Skip to main content
SP5007,785.76-0.17%DOW53,732.41-0.20%NASDAQ26,729.16-0.28%BTC$62,945.00-0.85%ETH$1,880.32-0.35%GOLD$4,432.00+0.26%OIL$82.40+1.42%
Smart Investors Daily
Sign InSign Up Free
GM

NASDAQ · GMDA

Gamida Cell Ltd.

Healthcare · Biotechnology

$0.03

Up+$0.00 (+0.00%)

Updated Aug 15, 2026, 4:02 AM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
4.34M
P/E ratio
-0.08
Dividend yield
0.00%
52-week range
— – —
Volume
19.05M
Avg. volume
21.71M

Price performance

GMDA price history

1M range · 0 trading sessions · Daily adjusted prices

GMDA does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest GMDA news

The latest Smart Investors Daily articles mentioning GMDA.

Stock researchCompany · Overview

GMDA research

Overview

Company profile and research snapshot.

Company profile

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
GMDA recent ratings
DateFirmRatingTarget
Jan 29, 2024JMP SecuritiesMarket Perform—
Dec 5, 2023NeedhamBuy—
Nov 15, 2023Piper SandlerOverweight—
Nov 15, 2023HC Wainwright & Co.Buy—
Sep 28, 2023JMP SecuritiesMarket Outperform—
Open full forecast

News briefing

No generated briefing is available yet.

businesswire.com · Oct 28, 2025

Gamida Cell Presents Positive Initial Results on Treating Severe Aplastic Anemia (SAA) with Omidubicel

LONDON--(BUSINESS WIRE)--Ayrmid Ltd. (“Ayrmid” or the “Company”), the parent company of Gamida Cell Inc., a cell therapy pioneer working to turn cells into powerful therapeutics, announced positive interim study results for omidubicel, a stem cell transplant therapy, in treating Severe Aplastic Anemia (SAA). The findings were shared by Dr. Ronit Simantov, Chief Medical and Scientific Officer of Gamida Cell, during a presentation at the 2025 Association for the Advancement of Blood & Biother.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By